地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:15172469628
邮箱:sales@amyjet.com

美国National Diagnostics(ND)向市场提供用于电泳的浓缩丙烯酰氨试剂的公司(推介于FASEB 1986);第一个研发出可生物降解的闪烁计数混合液;也第一个推出了可生物降解的橙子油来作为代替二甲苯的组织透明剂。
National Diagnostics is a principle world source for the development and manufacture of chemicals and related products for scientific research. We are particularly proud of the innovations we have made to improve laboratory safety and reduce the environmental impact of research. The National Diagnostics label on any product is an assurance of the highest level of quality and that all raw materials and finished products adhere to the most stringently controlled specifications.
National Diagnostics的主要产品包括:
Electrophoresis
Histology
Oxygen Assay
Liquid Scintillation
Electro-Optical
更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://fd.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸

Celprogen是一家生物技术公司,为心脏病学、肿瘤学、糖尿病和神经病学的再生医学研发干细胞研究和治疗产品。Celprogen的所有生物产品,包括干细胞、癌症干细胞、IPC和包括ECM在内的培养基,均在美国制造和生产。
CELPROGEN is a biotechnology company developing stem cell research and therapeutics products for regenerative medicine in cardiology, oncology, diabetes & neurology. All of Celprogen’s biological products, including stem cells, cancer stem cells, iPC’s & media including ECM’s, are manufactured and produced in the United States of America. CELPROGEN provides novel molecular diagnostics and therapeutic product development solutions for Biotechnology, Pharmaceutical, Invitro diagnostics and academic partnership for drug discovery.
Celprogen公司的主要产品:
3D Culture Systems
Biological Reagents
Cell-Based Assay Kits
Cosmetic
Devices
ExtracellularMatrix
Human Serum Albumin (HSA)
Life Science
Normal Cells
Organ Cultures
Patient-Derived Xenografts [PDX]
Therapeutics
Tumorgenicity
Vaccine Development
Xeno-Free Media
" data-original="http://fd.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Celprogen"> Celprogen
艾美捷科技特约代理F.S.T(Fine Science Tools)公司全系列产品。
F.S.T(Fine Science Tools)公司以追求高质量的产品和优质的服务为目标,为医护和科研人员提供医疗和动物精密手术器械,因而成为全球领先的手术器械生产商和供应商。F. S. T拥有手术剪、手术镊、骨科器械、手术刀及刀片、血管钳、持针钳等10余类共1000余种。
Fine Science Tools is the leading distributor of precision European surgical and microsurgical instruments to the scientific and biomedical research community.
Fine Science Tools公司的主要产品包括:
Scissors
Bone Instruments
Scalpels & Blades
Curettes, Spatulae & Probes
Pins
Wound Closure
Retractors
Vascular Instruments
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://fd.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Fine Science Tools"> Fine Science Tools
OncoImmunin products are continually expanding in response to the needs of the biomedical community, whether engaged in basic or developmental research. Many of OncoImmunin’s probes are a direct result of interactions between OncoImmunin scientists and the research community.
OncoImmunin的主要产品包括:
Patented Technologies
Apoptosis
Drug Delivery
Licensing and Screening
Cancer Metastasis
Cellular Cytotoxicity
Inflammation
Information
Viral Detection
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Kord-Valmark隶属于Bioplast Manufacturing公司,是专业化的培养皿生产商。
Kord-Valmark Labware Products by Bioplast Manufacturing, L.L.C. is a leading manufacturer of quality petri dishes. Our technical knowledge, experience and manufacturing capabilities – along with our superior mold design, precise process control and rigorous quality programs – allow us to manufacture the highest-quality products. Kord-Valmark’s disposable dishes provide unrivaled consistency, ease of use and exceptional value.
Kord-Valmark公司主要产品:
(1)Stackable Petri Dishes
Stackable polystyrene petri dishes are recommended for standard microbiology and general laboratory use
The stackable lid design ensures stability
Optically clear top and bottom viewing surfaces
Consistent flatness allows for even media distribution
Available in 3 sizes: 60 x 15 mm, 100 x 15 mm, and 100 x 25 mm
(2)Automation Petri Dishes
Automation and Slippable polystyrene petri dishes are recommended for standard microbiology and general laboratory use
Slippable lids provide a semi-stacking feature for hand use, while ensuring ease of use in automated equipment
Automation lids have no rim, ensuring ease of use in automated equipment
Select products are available with Side Arrows and/or ISO Mark Targets
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
< " data-original="http://fd.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="KORD-Valmark"> KORD-Valmark
Lumiprobe Corporation是美国一家高品质生物技术公司,专业提供分子生物学研究用的活性荧光染料。从2006年开始,Lumiprobe公司生产并销售生命科学研究和诊断学应用的优质化学药品。产品主要有:活性染料(Reactive Dye)和SYBR Green I 染料,用于寡核苷酸合成的亚磷酰胺,点击化学和其它试剂。
Since 2006, we manufacture and sell advanced chemicals for life science research, and diagnostics. Our catalog includes fluorescent dyes, phosphoramidites for oligonucleotide synthesis, Click chemicals, and other reagents. Most of the items are kept in stock, and ready for immediate shipping to worldwide locations.
主要产品有:
(1)Reactive dyes
Dye NHS esters
Dye azides
Dye alkynes
Dye maleimides
Dye hydrazides
Carboxylic acids
Amino dyes
Tetrazines
Cycloalkyne dyes
Miscellaneous dyes
(2)Click Chemistry reagents
Non-fluorescent azides
Non-fluorescent alkynes
(3)DNA
PCR/qPCR
Modified triphosphates
Phosphoramidites
CPG solid supports
(4)Miscellaneous reagents
Bifunctional crosslinkers
Auxiliary reagents
Proteomic reagents
(5)Pegylation & PEG Linkers
(6)Ready-to-use kits
Protein labeling kits
PCR/qPCR
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com

Neuromab是一家由NIH资助成立的单克隆抗体库。
The UC Davis/NIH NeuroMab Facility is a national monoclonal antibody-generating resource funded by the National Institutes of Health (NIH). The mission of the UC Davis/NIH NeuroMab Facility is to provide a unique neuroscience-based approach to generating mouse monoclonal antibodies optimized for use in mammalian brain (NeuroMabs). NeuroMabs are generated from mice immunized with synthetic and recombinant immunogens corresponding to components of the neuronal proteome as predicted from genomic and other large-scale cloning efforts. Comprehensive biochemical and immunohistochemical analyses of human, primate and non-primate mammalian brain are incorporated into the UC Davis/NIH NeuroMab Facility screening procedure. This yields a subset of mouse mAbs that are optimized for use in brain (i.e., NeuroMabs): for immunohistochemical- based imaging studies of protein localization in adult, developing and pathological brain samples, for biochemical analyses of subunit composition and post-translational modifications of native brain proteins, and for proteomic analyses of native brain protein networks.
Neuromab的主要产品包括:
Array Tomography
Model Organisms
Disease Targets
产品列表:
| 抗体名称 |
| Anti-5-formylcytidine, NeuroMab clone N358/68 |
| Anti-5-hydroxymethylcytidine, NeuroMab clone N297/59 |
| Anti-6xHis, NeuroMab clone N144/14 |
| Anti-ADAM11, NeuroMab clone N441/35 |
| Anti-ADAM22-cytoplasmic, NeuroMab clone N46/30 |
| Anti-ADAM22-extracellular, NeuroMab clone N57/2 |
| Anti-AGPS neo-epitope, NeuroMab clone N444/63 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/39 |
| Anti-Aldh1L1 (Aldehyde dehydrogenase family 1 member L1), NeuroMab clone N103/31 |
| Anti-Alg13, NeuroMab clone N442/28 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/80 |
| Anti-Alpha-2C adrenergic receptor, NeuroMab clone N330A/51 |
| Anti-AMIGO-1, NeuroMab clone L86/33 |
| Anti-AMIGO-1, NeuroMab clone L86/36 |
| Anti-AMIGO-1, NeuroMab clone L86A/37 |
| Anti-Ankyrin-B, NeuroMab clone N105/13 |
| Anti-Ankyrin-B, NeuroMab clone N105/17 |
| Anti-Ankyrin-G, NeuroMab clone N106/20 |
| Anti-Ankyrin-G, NeuroMab clone N106/36 |
| Anti-Ankyrin-G, NeuroMab clone N106/65 |
| Anti-Ankyrin-G, NeuroMab clone N106/43 |
| Anti-Ankyrin-R, NeuroMab clone N388A/10 |
| Anti-Ankyrin-R/G, NeuroMab clone N388A/27 |
| Anti-ANO3/TMEM16C, NeuroMab clone N454/91 |
| Anti-ANO5/TMEM16E, NeuroMab clone N421A/85 |
| Anti-ANO6/TMEM16F, NeuroMab clone N429/19 |
| Anti-ARHGAP4, NeuroMab clone N290B/25 |
| Anti-Arl13b, NeuroMab clone N295B/66 |
| Anti-Arx, NeuroMab clone N411/51 |
| Anti-ASIC1, NeuroMab clone N271/44 |
| Anti-ATAT1, NeuroMab clone N347/42 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/8 |
| Anti-Ataxin-1 11NQ, NeuroMab clone N76/3 |
| Anti-Ataxin-1 wild-type, NeuroMab clone N65/37 |
| Anti-ATF4, NeuroMab clone N360A/24 |
| Anti-BAF53a, NeuroMab clone N336B/83 |
| Anti-BAF53b, NeuroMab clone N332B/15 |
| Anti-Bassoon, NeuroMab clone L124/59 |
| Anti-BBS3/Arl6, NeuroMab clone N302/10 |
| Anti-BBS5, NeuroMab clone N304B/115 |
| Anti-BDNF, NeuroMab clone N450/53 |
| Anti-Beta1-spectrin, NeuroMab clone N385/21 |
| Anti-Beta4-spectrin, NeuroMab clone N393/2 |
| Anti-Beta4-spectrin, NeuroMab clone N393/76 |
| Anti-BKBeta2 potassium channel subunit, NeuroMab clone N53/32 |
| Anti-BKBeta3a potassium channel subunit, NeuroMab clone N40B/18 |
| Anti-BKBeta4 potassium channel, NeuroMab clone L18A/3 |
| Anti-Botch1/Chac1, NeuroMab clone N116/14 |
| Anti-Bral1, NeuroMab clone N364/10 |
| Anti-Bral1, NeuroMab clone N364/42 |
| Anti-Brevican, NeuroMab clone N294A/6 |
| Anti-Brevican, NeuroMab clone N294A/10 |
| Anti-CALB1/calbindin, NeuroMab clone L109/39 |
| Anti-CALB1/calbindin, NeuroMab clone L109/57 |
| Anti-CALB2/calretinin, NeuroMab clone L122/6 |
| Anti-CALB2/calretinin, NeuroMab clone L122/68 |
| Anti-CASK scaffolding protein, NeuroMab clone K56A/50 |
| Anti-Caspr/paranodin/neurexin IV, NeuroMab clone K65/35 |
| Anti-Caspr2/paranodin, NeuroMab clone K67/25 |
| Anti-Cav1.2 calcium channel, NeuroMab clone L57/46 |
| Anti-Cav1.2, NeuroMab clone N263/31 |
| Anti-Cav1.3 calcium channel, NeuroMab clone L48A/9 |
| Anti-Cav1.3 calcium channel, NeuroMab clone N38/8 |
| Anti-Cav3.1 Ca2+ channel, NeuroMab clone N178A/9 |
| Anti-Cav3.2 calcium channel, NeuroMab clone N55/10 |
| Anti-Cav1 calcium channel, NeuroMab clone N7/18 |
| Anti-Cav尾2 calcium channel subunit, NeuroMab clone N8b/1 |
| Anti-Cav3 calcium channel, NeuroMab clone N473/36 |
| Anti-Cav尾4 calcium channel, NeuroMab clone N10/7 |
| Anti-Cdkl5, NeuroMab clone EA7 |
| Anti-CDY1/2, NeuroMab clone N143/38 |
| Anti-CDY1/2/L1/L2, NeuroMab clone N143/36 |
| Anti-Celf4/Brunol4, NeuroMab clone N446/80 |
| Anti-FOS, NeuroMab clone N486/32 |
| Anti-FOS, NeuroMab clone N486/76 |
| Anti-Clcn3, NeuroMab clone N258/5 |
| Anti-Clcn4, NeuroMab clone N222/6 |
| Anti-Clcn5, NeuroMab clone N406/47 |
| Anti-CLN3, NeuroMab clone N380/87 |
| Anti-CLN6, NeuroMab clone N400/24 |
| Anti-CNGA1/3 cyclic nucleotide-gated channel, NeuroMab clone L36/12 |
| Anti-Collybistin, NeuroMab clone L120/12 |
| Anti-Collybistin, NeuroMab clone L120/30 |
| Anti-Contactin/F3 scaffold protein, NeuroMab clone K73/20 |
| Anti-Copper-transporting ATPase 1, NeuroMab clone L60/4 |
| Anti-Copper-transporting ATPase 2 (Copper pump 2, Wilsons disease-associated protein, NeuroMab clone L62/29 |
| Anti-Co-Rest/RCOR1 Transcriptional Co-Repressor, NeuroMab clone K72/8 |
| Anti-DEPDC5, NeuroMab clone N463/52 |
| Anti-Dicer, NeuroMab clone N167/7 |
| Anti-DLX1 transcription factor, NeuroMab clone L43/40 |
| Anti-DNAH1, NeuroMab clone N251/14 |
| Anti-DNAH7, NeuroMab clone N250/21 |
| Anti-DNAIC1, NeuroMab clone UNC 65.56.18.11 |
| Anti-DNMT3L, NeuroMab clone N117/9 |
| Anti-Doc2b, NeuroMab clone N150/21 |
| Anti-Dopamine D2 receptor, NeuroMab clone N186/29 |
| Anti-Dopamine D3 receptor, NeuroMab clone N331/19 |
| Anti-EAAC1, NeuroMab clone N420/24 |
| Anti-FGF11 (Fibroblast growth factor 11), NeuroMab clone N92/14 |
| Anti-FGF12/FHF1, NeuroMab clone N94/17 |
| Anti-FGF13 (Fibroblast growth factor 13), NeuroMab clone N91/27 |
| Anti-FGF13B/FHF2B, NeuroMab clone N225A/10 |
| Anti-FGF14/FHF4, NeuroMab clone N56/21 |
| Anti-Fig4/Sac3, NeuroMab clone N202/7 |
| Anti-Flrt3, NeuroMab clone N353/13 |
| Anti-Foxi2, NeuroMab clone N349/96 |
| Anti-Foxi3, NeuroMab clone N359/28 |
| Anti-Frataxin, NeuroMab clone N191/7 |
| Anti-GABA-A-R-Alpha1, NeuroMab clone N95/35 |
| Anti-GABA-A-R-Alpha2, NeuroMab clone N399/19 |
| Anti-GABA-A-R-Alpha4, NeuroMab clone N398A/34 |
| Anti-GABA-A-R-Alpha5, NeuroMab clone N415/24 |
| Anti-GABA-A-R-Alpha6, NeuroMab clone N229A/32 |
| Anti-GABA-A-R-Beta1, NeuroMab clone N96/55 |
| Anti-GABA-A-R-Beta2/3, NeuroMab clone 62-3G1 |
| Anti-GABA-A-R-Beta3, NeuroMab clone N87/25 |
| Anti-Delta GABA-A receptor, NeuroMab clone N151/3 |
| Anti-GABA-A-R-Epsilon, NeuroMab clone N413/67 |
| Anti-GABA-A-R-Gamma2L, NeuroMab clone N452/69 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/73 |
| Anti-GABA-A-R-Gamma2L/S, NeuroMab clone N452/30 |
| Anti-GABA-A-R-Pi, NeuroMab clone N431/64 |
| Anti- GABA-A-R-Theta, NeuroMab clone L123/109 |
| Anti-GABABR1 GABA-B receptor, NeuroMab clone N93A/49 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/2 |
| Anti-GABABR2 GABA-B receptor, NeuroMab clone N81/37 |
| Anti-GAD65/67, NeuroMab clone L127/12 |
| Anti-GAD67, NeuroMab clone L127/8 |
| Anti-Gamma-protocadherin-A3, NeuroMab clone N144/17 |
| Anti-Gamma-protocadherin-B2, NeuroMab clone N148/30 |
| Anti-Gamma-protocadherin-C3, NeuroMab clone N174B/27 |
| Anti-Gamma-protocadherin-C4, NeuroMab clone N193A/13 |
| Anti-Gephyrin, NeuroMab clone L106/83 |
| Anti-Gephyrin, NeuroMab clone L106/93 |
| Anti-Gephyrin, NeuroMab clone L106/4 |
| Anti-GFAP, NeuroMab clone N206A/8 |
| Anti-GFAP-R416WT, NeuroMab clone N206B/9 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/8 |
| Anti-GFP (Green fluorescent protein), NeuroMab clone N86/38 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/20 |
| Anti-GFP (green fluorescent protein), NeuroMab clone N86/44 |
| Anti-GIT1 scaffold protein, NeuroMab clone N39B/8 |
| Anti-GIT2 scaffold protein, NeuroMab clone N83/48 |
| Anti-GluA1/GluR1 glutamate receptor, NeuroMab clone N355/1 |
| Anti-GluA2/GluR2 glutamate receptor, NeuroMab clone L21/32 |
| Anti-KA2 kainate receptor, NeuroMab clone N279B/27 |
| Anti-GluN1/NR1 glutamate receptor, NeuroMab clone N308/48 |
| Anti-NR2A glutamate receptor, NeuroMab clone N327A/38 |
| Anti-GluN2A/NR2A glutamate receptor, NeuroMab clone N327/95 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/20 |
| Anti-GluN2B/NR2B glutamate receptor, NeuroMab clone N59/36 |
| Anti-GluN2C/NR2C, NeuroMab clone N422/18 |
| Anti- GluN3A/NR3A, NeuroMab clone N416/40 |
| Anti-Glycine receptor Alpha3, NeuroMab clone N424/45 |
| Anti-Glycine receptor Alpha3L, NeuroMab clone N424/48 |
| Anti-GRK6A/B, NeuroMab clone N142/28 |
| Anti-Gs protein alpha subunit, NeuroMab clone N192/12 |
| Anti-GST (Glutathione S-transferase), NeuroMab clone N100/13 |
| Anti-Haspin/GSG2, NeuroMab clone N128A/2 |
| Anti-HCN1 cyclic nucleotide-gated channel, NeuroMab clone N70/28 |
| Anti-HCN2 cyclic nucleotide-gated channel, NeuroMab clone N71/37 |
| Anti-HCN3 cyclic nucleotide-gated channel, NeuroMab clone N141/28 |
| Anti-HCN4 cyclic nucleotide-gated channel, NeuroMab clone N114/10 |
| Anti-Histone H2A.Z/V, NeuroMab clone N310/21 |
| Anti-Histone H2A.Z acetyl-Lys4/7/11, NeuroMab clone N299/39 |
| Anti-Histone H3.3, NeuroMab clone N158/28 |
| Anti-Histone H3 acetyl-Lys56, NeuroMab clone N307/12 |
| Anti-Histone H3-dimethyl-Arg8, NeuroMab clone N293/50 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/19 |
| Anti-Histone H3 pThr11, NeuroMab clone N123/48 |
| Anti-Histone H4-dimethyl-Arg3, NeuroMab clone N309A/21 |
| Anti-Homer1L, NeuroMab clone L113/27 |
| Anti-Homer1L, NeuroMab clone L113/13 |
| Anti-Homer1, NeuroMab clone L113/130 |
| Anti-ICK, NeuroMab clone N451/73 |
| Anti-Iduna/RNF146, NeuroMab clone N201/35 |
| Anti-INPP4b, NeuroMab clone N171/17 |
| Anti IP3 receptor type 1 NeuroMab clone L24/18 |
| Anti-IRSp53/BAIAP2, NeuroMab clone L117/1 |
| Anti-JIP-2/IB-2, NeuroMab clone N135/37 |
| Anti-JMJD2A, NeuroMab clone N154/32 |
| Anti-KCC2 transporter, NeuroMab clone N1/66 |
| Anti-KCC2 transporter, NeuroMab clone N1/12 |
| Anti-KChIP1 potassium channel, NeuroMab clone K55/7 |
| Anti-KChIP2 potassium channel subunit, NeuroMab clone K60/73 |
| Anti-KChIP3 potassium channel, NeuroMab clone K66/38 |
| Anti-KChIP4 K+ channel, NeuroMab clone N423/75 |
| Anti-KCNT1/Slo2.2/Slack K+ channel, NeuroMab clone N3/26 |
| Anti-KCNT2/Slo2.1/Slick sodium- and chloride-activated ATP sensitive potassium channel, NeuroMab clone N11/33 |
| Anti-KCNU1/Slo3 pH-sensitive maxi potassium channel, NeuroMab clone N2/16 |
| Anti-Keyhole limpet hemocyanin, NeuroMab clone N132A/12 |
| Anti-Kir2.1 potassium channel, NeuroMab clone N112B/14 |
| Anti-Kir2.2 potassium channel, NeuroMab clone N124B/38 |
| Anti-Kir2.3 potassium channel, NeuroMab clone N25/35 |
| Anti-Kir2.4 potassium channel, NeuroMab clone N465/11 |
| Anti-Kir3.3 potassium channel, NeuroMab clone N455/15 |
| Anti-Kir6.1 potassium channel, NeuroMab clone N366/60 |
| Anti-Kir6.2 potassium channel, NeuroMab clone N363/71 |
| Anti-Kirrel3 short and long, NeuroMab clone N321C/49 |
| Anti-Kirrel3 short isoform 3, NeuroMab clone N320/48 |
| Anti-Kv1.1 potassium channel subunit, NeuroMab clone K20/78 |
| Anti-Kv1.1 potassium channel (external), NeuroMab clone K36/15 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K14/16 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone L76/36 |
| Anti-Kv1.3 potassium channel, NeuroMab clone L23/27 |
| Anti-Kv1.4 potassium channel subunit, NeuroMab clone K13/31 |
| Anti-Kv1.4 potassium channel (extracellular), NeuroMab clone L71/5 |
| Anti-Kv1.5 potassium channel, NeuroMab clone K7/45 |
| Anti-Kv1.6 potassium channel subunit, NeuroMab clone K19/36 |
| Anti-Kv1.7 potassium channel, NeuroMab clone N471/27 |
| Anti-Kv11.3 potassium channel, NeuroMab clone N447/24 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L83/11 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone K89/34 |
| Anti-Kv2.1 potassium channel subunit, NeuroMab clone L80/21 |
| Anti-Kv2.1 potassium channel (external), NeuroMab clone K39/25 |
| Anti-Kv2.2 potassium channel, NeuroMab clone K37/89 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372C/51 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/60 |
| Anti-Kv2.2 potassium channel, NeuroMab clone N372B/1 |
| Anti-Kv3.1b potassium channel, NeuroMab clone N16b/8 |
| Anti-Kv3.2 potassium channel, NeuroMab clone N410/17 |
| Anti-Kv3.3 potassium channel, NeuroMab clone N375/67 |
| Anti-Kv3.4 potassium channel, NeuroMab clone N72/16 |
| Anti-Kv4.2 potassium channel subunit, NeuroMab clone L28/4 |
| Anti-Kv4.2 potassium channel (external), NeuroMab clone K57/1 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/41 |
| Anti-Kv4.3 potassium channel subunit, NeuroMab clone K75/30 |
| Anti-Kv6.1 potassium channel, NeuroMab clone N474/27 |
| Anti-Kv6.4 potassium channel, NeuroMab clone N458/10 |
| Anti-KCNQ1 potassium channel, NeuroMab clone N37A/10 |
| Anti-KCNQ2 potassium channel, NeuroMab clone N26A/23 |
| Anti-KCNQ4 potassium channel, NeuroMab clone N43/6 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/88 |
| Anti-Kv8.2 potassium channel, NeuroMab clone N448/50 |
| Anti-Kv9.1 potassium channel, NeuroMab clone N461/19 |
| Anti-Kv9.2 potassium channel, NeuroMab clone N460/19 |
| Anti-Kvβ1.1 potassium channel subunit, NeuroMab clone K9/40 |
| Anti-Kv1.2 potassium channel subunit, NeuroMab clone K47/42 |
| Anti-Kv尾2 potassium channel, NeuroMab clone K17/70 |
| Anti-Laforin, NeuroMab clone N84/37 |
| Anti-LAR/PTPRF, NeuroMab clone N165/38 |
| Anti-Lgi1, NeuroMab clone N283/7 |
| Anti-Lhx6.1, NeuroMab clone N228A/16 |
| Anti-LRP4 (cytoplasmic), NeuroMab clone N164/6 |
| Anti-LRP4 (extracellular), NeuroMab clone N207/27 |
| Anti-LRRK1, NeuroMab clone N341/37 |
| Anti-LRRK1, NeuroMab clone N341/12 |
| Anti-LRRK2/Dardarin, NeuroMab clone N241A/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone N231B/34 |
| Anti-LRRK2/Dardarin, NeuroMab clone 8G10 |
| Anti-LRRK2/Dardarin, NeuroMab clone N138/6 |
| Anti-LRRK2/Dardarin-pSer910, NeuroMab clone 1D8 |
| Anti-LRRTM2, NeuroMab clone N209C/35 |
| Anti-LRRTM4, NeuroMab clone N205B/22 |
| Anti-Mad3, NeuroMab clone N129A/6 |
| Anti-Mad3, NeuroMab clone N129/15 |
| Anti-Malin, NeuroMab clone N85/18 |
| Anti-MBP (Maltose-binding protein), NeuroMab clone N128A/4 |
| Anti-MAP3K12, NeuroMab clone N377/20 |
| Anti-MAP3K12, NeuroMab clone N377/83 |
| Anti-MECP2, NeuroMab clone N227/21 |
| Anti-MESD, NeuroMab clone N88/12 |
| Anti-MFF, NeuroMab clone N382/14 |
| Anti-MFF (exon 1), NeuroMab clone N382/69 |
| Anti-MGL, NeuroMab clone N90/20 |
| Anti-mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/3 |
| Anti- mGluR1/5 (group I) glutamate receptor, NeuroMab clone N75/33 |
| Anti-Miro2, NeuroMab clone N384/63 |
| Anti-MiRP4 potassium channel, NeuroMab clone N472/88 |
| Anti-Mitofusin-1 (Mfn1), NeuroMab clone N111/24 |
| Anti-Mitofusin-2 (Mfn2), NeuroMab clone N153/5 |
| Anti-MMACHC, NeuroMab clone N230/21 |
| Anti-MMP9 metalloproteinase, NeuroMab clone L51/82 |
| Anti-MOG, NeuroMab clone L94/54 |
| Anti-Mortalin/GRP75, NeuroMab clone N52A/42 |
| Anti-MPP8, NeuroMab clone N119/44 |
| Anti-NALCN, NeuroMab clone N185/7 |
| Anti-Nav1.1 sodium channel, NeuroMab clone K74/71 |
| Anti-Nav1.2 sodium channel, NeuroMab clone K69/3 |
| Anti-Nav1.4 sodium channel, NeuroMab clone N255/38 |
| Anti-Nav1.5 sodium channel, NeuroMab clone N397/19 |
| Anti-Nav1.6 sodium channel, NeuroMab clone K87A/10 |
| Anti-Nav1.7 sodium channel, NeuroMab clone N68/6 |
| Anti-Nav1.8 sodium channel, NeuroMab clone N134/12 |
| Anti-Navbeta1 Na+ channel, NeuroMab clone N405/74 |
| Anti-Navbeta2 Na+ channel, NeuroMab clone N395/68 |
| Anti-Navbeta3 Na+ channel, NeuroMab clone N396/29 |
| Anti-Navbeta4 sodium channel, NeuroMab clone N168/6 |
| Anti-NCKX4, NeuroMab clone N414/25 |
| Anti-Neuregulin-CRD (Cysteine-rich domain, Type III), NeuroMab clone N126B/31 |
| Anti-Neuregulin-HBD (Heparin-binding domain, Type I/II), NeuroMab clone N120A/9 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/1 |
| Anti-Neurexin-1-Beta, NeuroMab clone N170A/26 |
| Anti-Neuroligin-1, NeuroMab clone N97A/31 |
| Anti-Neuroligin-2, NeuroMab clone L107/39 |
| Anti-Neuroligin-3, NeuroMab clone N110/29 |
| Anti-Neuroligin-4*, NeuroMab clone N98/47 |
| Anti-Neuroligin-4*, NeuroMab clone N98/7 |
| Anti-NGL-1 (Netrin-G1 ligand), NeuroMab clone N49A/21 |
| Anti-NGL-2 (Netrin-G2 ligand) NeuroMab clone N50/36 |
| Anti-NGL-3 (Netrin-G3 ligand), NeuroMab clone N51/6 |
| Anti-NKCC1, NeuroMab clone N161/20 |
| Anti-NOS1/nNOS, NeuroMab clone L121/25 |
| Anti-NOS1/nNOS, NeuroMab clone L121/42 |
| Anti-Notch1, NeuroMab clone N253/32 |
| Anti-Npas4, NeuroMab clone N408/62 |
| Anti-Npas4, NeuroMab clone N408/79 |
| Anti-Neuropeptide Y, NeuroMab clone L115/13 |
| Anti-NPY2R, NeuroMab clone L119/106 |
| Anti-NrCAM, NeuroMab clone N343/26 |
| Anti-NSD1, NeuroMab clone N312/10 |
| Anti-NSD3, NeuroMab clone N348/82 |
| Anti-OCRL/INPP5b, NeuroMab clone N166A/26 |
| Anti-Olig1, NeuroMab clone N149/25 |
| Anti-Pan-Ankyrin, NeuroMab clone N388A/60 |
| Anti-Pancortin, NeuroMab clone K96/7 |
| Anti-Pan-FHF-A, NeuroMab clone N235/22 |
| Anti-Pan-Gamma-protocadherin-A, NeuroMab clone N144/32 |
| Anti-Pan-Gamma-protocadherin, NeuroMab clone N159/5 |
| Anti-Pan-GRK, NeuroMab clone N145/20 |
| Anti-Pan-KChIP potassium channel, NeuroMab clone K55/82 |
| Anti-Pan-Kv potassium channel, NeuroMab clone K40/17 |
| Anti-Pan-Kvbeta potassium channel, NeuroMab clone K25/73 |
| Anti-Pan-MAGUK scaffold proteins, NeuroMab clone K28/86 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/40 |
| Anti-Pan-Nav1 sodium channel, NeuroMab clone N419/78 |
| Anti-pan-Neurofascin, NeuroMab clone L11A/41 |
| Anti-Pan-Neurofascin (external), NeuroMab clone A12/18 |
| Anti-Pannexin-2, NeuroMab clone N121A/1 |
| Anti-Pannexin-2, NeuroMab clone N121A/31 |
| Anti-Pan-PTPR, NeuroMab clone N165/43 |
| Anti-Pan-QKI, NeuroMab clone N147/6 |
| Anti-Pan-SAPAP, NeuroMab clone N127/31 |
| Anti-pan-Shank (SH3 and multiple ankyrin repeat domains protein) scaffold protein, NeuroMab clone N23B/49 |
| Anti-Pan-Synapsin, NeuroMab clone L125/129 |
| Anti-Pan-Thyroid hormone receptor, NeuroMab clone N403/63 |
| Anti-PARIS/ZNF746, NeuroMab clone N196/16 |
| Anti-Parvalbumin, NeuroMab clone L114/3 |
| Anti-Parvalbumin, NeuroMab clone L114/81 |
| Anti-PEX6, NeuroMab clone N233/8 |
| Anti-PEX7, NeuroMab clone N232/9 |
| Anti-Phosphoserine-2-OEt, NeuroMab clone N257/25 |
| Anti-Phosphoserine-2-OH, NeuroMab clone N259/48 |
| Anti-Phosphoserine-2-OMe, NeuroMab clone N262/16 |
| Anti-PhyH/PAHX, NeuroMab clone N210/5 |
| Anti-PICK1 scaffold, NeuroMab clone L20/8 |
| Anti-PINK1, NeuroMab clone N4/15 |
| Anti-PINK1, NeuroMab clone N4/49 |
| Anti-PINK1, NeuroMab clone N4/19 |
| Anti-PINK1, NeuroMab clone N357/6 |
| Anti-Proser1, NeuroMab clone N456/39 |
| Anti-Prrt2, NeuroMab clone N485/22 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/30 |
| Anti-PSD-93/Chapsyn-110 scaffold protein, NeuroMab clone N18/28 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/43 |
| Anti-PSD-95 MAGUK scaffold protein, NeuroMab clone K28/74 |
| Anti-QKI-5-NLS, NeuroMab clone N195A/16 |
| Anti-QKI-6, NeuroMab clone N182/17 |
| Anti-QKI-7, NeuroMab clone N183/15 |
| Anti-QKI-7b, NeuroMab clone N194/11 |
| Anti-RBM17/SPF45, NeuroMab clone N219/5 |
| Anti-REEP, NeuroMab clone N326D/13 |
| Anti-REEP1, NeuroMab clone N345/51 |
| Anti-REEP1/2, NeuroMab clone N326D/29 |
| Anti-REEP2, NeuroMab clone N326D/2 |
| Anti-Rem2, NeuroMab clone N324/2 |
| Anti-RGS14, NeuroMab clone N133/21 |
| Anti-RGS14, NeuroMab clone N133/35 |
| Anti-Rufy3, NeuroMab clone N483/84 |
| Anti-Rufy3, NeuroMab clone N483/126 |
| Anti-Rufy3, NeuroMab clone N483/26 |
| Anti-S100A5, NeuroMab clone N176A/35 |
| Anti-SALM2 synaptic adhesion-like molecule, NeuroMab clone N52B/27 |
| Anti-SALM5/LRFN5, NeuroMab clone N140A/12 |
| Anti-SAP102 MAGUK scaffold protein, NeuroMab clone N19/2 |
| Anti-SAP97 scaffold protein, NeuroMab clone K64/15 |
| Anti-SAPAP1, NeuroMab clone N238/29 |
| Anti-SAPAP1, NeuroMab clone N238/30 |
| Anti-SAPAP1/2, NeuroMab clone N238/31 |
| Anti-SAPAP2, NeuroMab clone N459/84 |
| Anti-SAPAP3, NeuroMab clone L126/93 |
| Anti-SCG10/stathmin-2, NeuroMab clone L5/1 |
| Anti-SH3GL1, NeuroMab clone K51/1 |
| Anti-Shank1/ SPANK-1/Synamon/SSTRIP scaffold protein, NeuroMab clone N22/21 |
| Anti-Shank1 and Shank3, NeuroMab clone N367/51 |
| Anti-Shank2/ProSAP1/Spank-3/CortBP1 scaffold protein,NeuroMab clone N23B/6 |
| Anti-Shank3 scaffold protein, NeuroMab clone N69/46 |
| Anti-Shank3, NeuroMab clone N367/62 |
| Anti-SK2 potassium channel, NeuroMab clone K78/29 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/23 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/48 |
| Anti-Slo1/BKAlpha potassium channel, NeuroMab clone L6/60 |
| Anti-Snapin (SNAP25 binding protein), NeuroMab clone L8/15 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/37 |
| Anti-SNAT1 Neurotransmitter Transporter NeuroMab clone N104/32 |
| Anti-SST/Somatostatin, NeuroMab clone L111/118 |
| Anti-S-tag, NeuroMab clone N56/9 |
| Anti-Stonin-2, NeuroMab clone N346/9 |
| Anti-SUR1, NeuroMab clone N289/16 |
| Anti-SUR1 and SUR2B, NeuroMab clone N323A/31 |
| Anti-SUR2A, NeuroMab clone N319A/14 |
| Anti-SUR2B, NeuroMab clone N323B/20 |
| Anti-SVOP, NeuroMab clone N356/9 |
| Anti-SVOP, NeuroMab clone N356/23 |
| Anti-Synapsin-III, NeuroMab clone L125/121 |
| Anti-Synaptotagmin-10, NeuroMab clone N269/73 |
| Anti-Synaptotagmin-12, NeuroMab clone N277/7 |
| Anti-Synaptotagmin-3, NeuroMab clone N278/19 |
| Anti-Synaptotagmin-5, NeuroMab clone N274/8 |
| Anti-Synaptotagmin-6, NeuroMab clone N270/47 |
| Anti-Synaptotagmin-7, NeuroMab clone N275/14 |
| Anti-Synaptotagmin-9, NeuroMab clone N276A/15 |
| Anti-SynCAM1 cell adhesion molecule, NeuroMab clone L45/30 |
| Anti-SynCAM4, NeuroMab clone N244/5 |
| Anti-SynDIG1/Tmem90b, NeuroMab clone L42/17 |
| Anti-SynDIG3/Tmem91, NeuroMab clone N160/21 |
| Anti-SynDIG4, NeuroMab clone L102/45 |
| Anti-Tafazzin, NeuroMab clone N173B/13 |
| Anti-TALK1 potassium channel, NeuroMab clone N466/14 |
| Anti-TARPGamma2/Stargazin, NeuroMab clone N245/1 |
| Anti-TARPGamma2/4/8, NeuroMab clone N245/36 |
| Anti-TASK1 potassium channel, NeuroMab clone N374/48 |
| Anti-Tauro-GM2, NeuroMab clone N175/9 |
| Anti-THAP1, NeuroMab clone N325B/65 |
| Anti-THIK-2 potassium channel, NeuroMab clone N468/37 |
| Anti-Thioredoxin, NeuroMab clone N245/44 |
| Anti-Thorase (Atad1), NeuroMab clone N125/10 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/13 |
| Anti-Thyroid hormone receptor beta1, NeuroMab clone N402/46 |
| Anti- TRAAK potassium channel, NeuroMab clone N445/27 |
| Anti-TRAK1, NeuroMab clone N389/9 |
| Anti-TRAK2, NeuroMab clone N390/43 |
| Anti-TRESK potassium channel, NeuroMab clone N467/1 |
| Anti-TRIP8b (constant), NeuroMab clone N212/7 |
| Anti-TRIP8b (constant), NeuroMab clone N212/17 |
| Anti-TRIP8b (exon 1a/5 junction), NeuroMab clone N291C/22 |
| Anti-TRIP8b (exon 1b), NeuroMab clone N212A/34 |
| Anti-TRIP8b (exon 4), NeuroMab clone N212/3 |
| Anti-TrpC1 calcium channel, NeuroMab clone 1F1 |
| Anti-TrpC4 calcium channel, NeuroMab clone N77/15 |
| Anti-TrpC5 calcium channel, NeuroMab clone N67/15 |
| Anti-TrpC7 calcium channel, NeuroMab clone N64A/36 |
| Anti-TrpM4, NeuroMab clone L88/86 |
| Anti-TrpM6, NeuroMab clone N470/22 |
| Anti-TrpM7 ion channel and Ser/Thr kinase, NeuroMab clone N74/25 |
| Anti-TRPML3/Mucolipin-3, NeuroMab clone N268/19 |
| Anti-TrpV1, NeuroMab clone N221/17 |
| Anti-TrpV1, NeuroMab clone N221/12 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/4 |
| Anti-TrpV3 cation channel, NeuroMab clone N15/39 |
| Anti-TWIK-2 potassium channel, NeuroMab clone N469/28 |
| Anti-Uncx, NeuroMab clone N155/9 |
| Anti-VAChT vesicular acetylcholine transporter, NeuroMab clone N6/38 |
| Anti-VAChT, NeuroMab clone N425/45 |
| Anti-VAPA, NeuroMab clone N479/12 |
| Anti-VAPA, NeuroMab clone N479/22 |
| Anti-VAPA/B, NeuroMab clone N479/107 |
| Anti-VDAC1, NeuroMab clone N152B/23 |
| Anti-Versican, NeuroMab clone N351/23 |
| Anti-Versican, NeuroMab clone N351/24 |
| Anti-VGAT, NeuroMab clone L118/80 |
| Anti-VGAT, NeuroMab clone L118/66 |
| Anti-VGlut1, NeuroMab clone N28/9 |
| Anti-VGlut2, NeuroMab clone N29/29 |
| Anti-VGlut3, NeuroMab clone N34/34 |
| Anti-VIP, NeuroMab clone L108/92 |
| Anti-VMAT1, NeuroMab clone N440/21 |
| Anti-VMAT1, NeuroMab clone N440/61 |
| Anti-Slc18a2/VMAT2, NeuroMab clone N449/73 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/21 |
| Anti-Zebrafish VSP/TPTE, NeuroMab clone N432/63 |
| Anti-WAVE1/SCAR, NeuroMab clone K91/36 |
| Anti-WNK1, NeuroMab clone N391/68 |
| Anti-WRN, NeuroMab clone N428/12 |
| Zebrafish PSD Marker, NeuroMab clone N286/74 |
| Anti-Zinedin/Striatin-4, NeuroMab clone K88/64 |
| Anti-ZIP3, NeuroMab clone N476/9 |
| Anti-ZNF423, NeuroMab clone N328B/37 |

艾美捷科技特约代理Exbio公司产品。Exbio公司是捷克著名的抗体生产商,该公司于学术机构展开广泛的合作,在杂交瘤、重组蛋白和抗体方面始终保持研发力度,持续不断地推出新的产品。
抗体产品主要包括以下领域:Human Immunology、Rodent Immunology、Veterinary Reagents、
Cell Biology、Isotype Control Reagents等,此外还有重组蛋白、试剂盒,以及OEM服务。
EXBIO manufactures and supplies antibodies for world-wide distribution. Sales on an OEM basis and in bulk quantity is the core business activity of the company. Strong Research & Development (hybridoma technology, construction of recombinant proteins and antibodies) in co-operation with academic institutions ensures the continuous addition of important new products.
EXBIO entered the antibody market as a spin-off company of Czech Academy of Sciences in 1990. Continuous economic growth resulted in the movement to our own brand new manufacture facility on February 2003.
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://fd.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Exbio"> Exbio
Exiqon公司属于QIAGENE集团,该公司在microRNA表达分析领域具有国际领先地位,于2005年获得了Ernst&Youngs生物类大奖。Exiqon公司提供miRCURY系列产品,专门用于研究microRNA的表达、分布和功能。Exiqon的microRNA芯片亲和力更高,使用基于LNA专利技术的捕获探针。
Exiqon's products and services are used by researchers in academia, biotech and pharmaceutical companies around the world to make groundbreaking discoveries about the correlation between gene activity and the development of disease. Taking advantage of our proprietary LNA™ technology, our product lines offer superior specificity and sensitivity for analysis of microRNA, mRNA and long non-coding RNA. Exiqon's products and services encompass the entire workflow from sample preparation to expression analysis (Sequencing, Array and qPCR), detection and functional analysis both in vitro and in vivo. Exiqon Services offers expertise in RNA Next Generation Sequencing, microRNA profiling and biomarker discovery from clinical samples.
Exiqon公司的主要产品包括:
microRNA products
mRNA & lncRNA products
Customer support
LNA™ oligos
RNA services
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://fd.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Exiqon"> Exiqon地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:18372041646
传真:13212737804
邮箱:sales@amyjet.com
0.3568